Clinical consequences of targeting IL-17 and TH17 in autoimmune and allergic disorders

37Citations
Citations of this article
73Readers
Mendeley users who have this article in their library.

Abstract

The TH17 lineage of T cells and its canonical cytokine IL-17 have been the focus of many recent studies in autoimmune, allergic, and infectious disease. In this review, we will briefly discuss the current knowledge about the role of these cells and IL-17 in a spectrum of disorders. It is clear that IL-17 plays pathogenic roles in certain conditions while the same pathway is critically important to immunity in others. Targeting of T H17 cells or IL-17 therapeutically may impart many benefits, but this approach is not without potentially serious implications regarding host defense. These issues will be discussed herein as we evaluate pharmacological approaches targeting this pathway that are just beginning to be fully tested in human disease. © 2013 Springer Science+Business Media New York.

Cite

CITATION STYLE

APA

Robinson, K. M., Manni, M. L., Biswas, P. S., & Alcorn, J. F. (2013). Clinical consequences of targeting IL-17 and TH17 in autoimmune and allergic disorders. Current Allergy and Asthma Reports, 13(6), 587–595. https://doi.org/10.1007/s11882-013-0361-0

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free